Specify a stock or a cryptocurrency in the search bar to get a summary
Sight Sciences Inc
SGHTSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. Address: 4040 Campbell Avenue, Menlo Park, CA, United States, 94025
Analytics
WallStreet Target Price
5.46 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SGHT
Dividend Analytics SGHT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SGHT
Stock Valuation SGHT
Financials SGHT
Results | 2019 | Dynamics |